Nektar Therapeutics (NAS:NKTR)
$ 1.02 0.01 (0.99%) Market Cap: 186.30 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.74 GF Score: 56/100

Nektar Therapeutics Corporate Call - COVID Analyst Event Transcript

Oct 27, 2020 / 12:30PM GMT
Release Date Price: $16.48 (-2.89%)
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Nektar Therapeutics COVID call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Corporate Affairs.

Ma'am, you may begin.

Jennifer Ruddock
Nektar Therapeutics - SVP of Strategy & Corporate Affairs

Thank you, Crystal. Good morning, everyone, and thank you for joining us this morning. Presenting today are Howard Robin, our President and CEO; and Dr. Jonathan Zalevsky, our Head of R&D. Also joining us are key experts from our COVID Scientific Advisory Committee; Dr. Richard Bucala from the Yale School of Medicine; and Dr. Robert Gallo from the University of Maryland School of Medicine.

On today's call, we expect to make forward-looking statements regarding our business, timing and plans for future clinical trials; timing and plans for future clinical data presentations, the therapeutic potential of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot